SANTA CRUZ, Calif., April 28, 2015 /PRNewswire/ — SomaGenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA.
There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression profiling and diagnostic purposes. There are many advantages to using NGS, including unlimited multiplexing, high sensitivity, sequence specificity and ability to detect miRNA sequence editing. Targeted NGS brings these advantages to the quantification of any specific group of sequences of interest. However, sequence bias in the construction of the small RNA libraries used in sequencing has so far limited the utility of NGS, both targeted and non-targeted. This bias gives distorted small RNA profiles and renders some species of RNA that might be good biomarkers unavailable for accurate quantification.
“RealSeq–T improves the accuracy and sensitivity of targeted NGS compared to current methods and provides accurate quantification of all miRNA species of interest,” said Dr. Brian Johnston, CEO of SomaGenics. “We are excited [click to continue…]
Dr. Davide Marini, co-founder and Chief Executive Officer of Firefly BioWorks announced today the creation of the Firefly Frontiers Grant:
“We are excited to provide financial support to researchers for expanding the horizons of microRNA research. We encourage applicants to explore high-impact questions and those high-risk explorations that would not be normally funded through a traditional academic route”.
The Firefly Frontiers Grant is a $10,000 award in products and services to support exploratory studies in the area of microRNAresearch. It is open to principal investigators, postdoctoral and graduate students in academic and non-profit research institutions. The company’s flagship product, FirePlex™ miRSelect, enables high-throughput and targeted microRNA profiling on a flow cytometer. FirePlex™ miRSelect scales easily [click to continue…]
Life Technologies has 2 TaqMan® qPCR consumables grants available for European research teams*. You have the opportunity to make your project come to life with a grant of either 10,000 or 5,000 euros*.
To apply for the grant you will need to tell Life Technologies about a specific challenge you would like to tackle, what you aim to achieve and outline your motivation for pursuing your study.
Applications will be accepted for a very limited time. Pre-registration is open now. If you would like to pre-register for the TaqMan® Grant please visit www.taqmangrant.com
*Please see Terms and Conditions, available on the TaqMan® Grant website for country eligibility and further details.
Incoming search terms for this article:
GenomeWeb Daily News
…which awarded nearly $1.5 million in one-year Small Business Innovation Research grants to companies playing in the RNAi and microRNA fields… (read more)